The report documents how 340B-eligible hospital outpatient departments earn tremendous profits from the Medicare Part B program. Physician offices, which also receive Part B reimbursements, are not as fortunate.

The OIG focuses on how the Medicare program could save money by sharing in these mega-profits. But as my summary chart below shows, Medicare appears to be providing incentives for shifts in cancer care treatment locations.

As usual, we don’t know if needy patients are benefiting from hospitals’ excess Medicare 340B profits. The OIG even reminds us three times in its report: “The 340B statute does not restrict how covered entities may use these funds.” Unfortunately, the Health Resources and Services Administration’s recent Omnibus Guidance didn’t bother to require that hospitals use 340B funds help the neediest patients access valuable medicines. Money, so they say, is the root of all evil today.340B, IT'S A GAS

As you may know, the 340B program mandates that pharmaceutical manufacturers provide outpatient drugs to certain healthcare entities—known as eligible covered entities—at significant discounts. To be eligible for program participation, providers must be one of six designated hospital types or receive federal grants administered by different agencies within the Department of Health & Human Services (HHS). Hospitals must meet additional eligibility criteria that vary by hospital type.

Hospital outpatient departments can purchase oncology drugs using the 340B drug pricing program. Currently, such clinics must treat “eligible patients,” appear on the hospital’s Medicare Cost Report as a “child site,” be registered on the Office of Pharmacy Affairs (OPA) database, and meet certain other criteria.

GRAB THAT CASH WITH BOTH HANDS

Medicare is the largest payer of provider-administered specialty drugs. Its Part B program covers provider-administered injectable and certain other drugs.

In looking only at Medicare Part B program spending, the new OIG study found that hospital outpatient settings received discounted 340B pricing on an astounding 48% of all drugs. By comparison, physician offices received 340B pricing on only 2% of drugs. Here’s the data from page 8 of the report:

For 340B hospitals, average gross margin (reimbursements minus acquisition cost) from their $3.2 billion in 340B purchases was 58%. For about one-quarter of the Healthcare Common Procedure Coding System (HCPCS) J-codes, gross margin exceeded 100%. Money, it's a hit!

The OIG report exposes detailed information on the gross margin for five unnamed cancer drugs. I computed the gross profit and gross margin for the 340B-covered entities (mostly hospitals) compared with the noncovered entities (mostly physician offices).

As you can see from the chart below, gross profit per beneficiary was 7 to 15 times larger at 340B-covered entities. Gross margins ranged from 28% to 55%, compared with gross margins of less than 4% for noncovered entities.

[Click to Enlarge]

SHARE IT FAIRLY

In section 6.2.2. (page 88) of our 2015-16 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors, I explain how economic pressures are (1) encouraging oncologists to sell their practices to hospitals, and (2) shifting care from community practices to hospital outpatient departments. Make sure you check out Exhibit 59 of our report for a look at shifting sites of care for the top five specialty drugs paid under the medical benefit.

“…the acquisition of oncology practices by 340B institutions may have the potential of unintended, market-distorting consequences by creating an uneven practice reimbursement environment favoring the survival of a 340B practice over a non-340B practice…”

BUT DON'T TAKE A SLICE OF MY PIE

For a subset of the J-codes, the OIG found that a beneficiary’s coinsurance was greater than the hospital’s acquisition cost. In a footnote, the OIG tartly states: “We did not confirm whether beneficiaries in fact paid the Part B coinsurance for 340B-purchased drugs.”

“To ensure that the program’s funds are being used appropriately, Congress should require that hospitals fully disclose how they use their 340B pharmacy profits. By allowing hospital’s to retain and then spend all 340B pharmacy profits, neither Medicare nor patients benefit from 340B drug discounts...It’s time to modernize the 340B program and help the neediest patients access valuable medicines.”

DISCLAIMERThe analyses on this website are based on information and data that are in the public domain. Any conclusions, findings, opinions, or recommendations are based on our own experienced and professional judgment and interpretations given the information available. While all information is believed to be reliable at the time of writing, the information provided here is for reference use only and does not constitute the rendering of legal, financial, commercial, or other professional advice by Pembroke Consulting, Inc., Drug Channels Institute, or the author. Any reliance upon the information is at your own risk, and Pembroke Consulting, Inc., Drug Channels Institute, and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. Pembroke Consulting, Inc., and Drug Channels Institute do not make investment recommendations, on this website or otherwise. Nothing on this website should be interpreted as an opinion by Pembroke Consulting, Inc., Drug Channels Institute, or the author on the investment prospects of specific companies.

The comments contained on this site come from members of the public and do not necessarily reflect the views of Drug Channels Institute or the author. Neither Drug Channels Institute nor the author endorse or approve of their content. Drug Channels Institute and the author reserve the right to remove or block comments, but are under no obligation to explain individual moderation decisions.

The public domain use of our materials includes linking to our website. You do not need to obtain special permission to link to the Drug Channels site. The material on this site is protected by copyright law. Unauthorized reproduction or distribution of this material may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. This report may be cited in commercial documents with full and appropriate attribution. We do not intend to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws. We do not permit our articles to be republished without prior written permission.

The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels Institute, or any of its employees.